For Investors

Close

Incyte International Locations

NORTH AMERICA—
HEADQUARTERS

FINLAND

JAPAN

SWEDEN

EUROPE—
HEADQUARTERS

FRANCE

THE NETHERLANDS

SWITZERLAND

AUSTRIA

GERMANY

NORWAY

UNITED KINGDOM

DENMARK

ITALY

SPAIN

Home > Investor Relations

Investor Relations

Overview

Incyte is a global biopharmaceutical company founded on the premise that investment in strong science and the relentless pursuit of R&D excellence can translate into new solutions that can positively affect patients’ lives.

Events & Presentations

Upcoming

Monday January 13, 2020 at 8:30 AM PST
J. P. Morgan 38th Annual Healthcare Conference

View All Events

Prior

Wednesday December 4, 2019 at 8:30 AM EST
Piper Jaffray 31st Annual Healthcare Conference

Tuesday November 12, 2019 at 8:35 AM MST
Credit Suisse 28th Annual Healthcare Conference

Tuesday October 29, 2019 at 8:00 AM EDT
Q3 2019 Incyte Corporation Earnings Conference Call

View All Events

Press Releases

December 5, 2019

Incyte to Present at Upcoming Investor Conference


November 27, 2019

Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma


November 25, 2019

Data from Incyte’s Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting


View All Releases

Investor Contacts

Michael Booth D.Phil
Division VP, Investor Relations & Corporate Responsibility
Phone: 302.498.5914
mbooth@incyte.com

Lauren Ayala, MBA
Senior Director, Investor Relations & Corporate Responsibility
Phone: 302.498.6141
layala@incyte.com

Christine Chiou
Senior Director, Investor Relations
Phone: 302.274.4773
cchiou@incyte.com

Copyright West LLC. Minimum 15 minutes delayed.

Annual Reports

Quarterly Reports

RSS Feeds


All Press Releases

All Events

All SEC Filings